Purpose

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Criteria


Inclusion Criteria:

- SCREENING/PRE-SCREENING REGISTRATION:

- Patients must have pathologically proven squamous cell carcinoma (SCCA) cancer of the
lung confirmed by tumor biopsy and/or fine-needle aspiration; disease must be stage IV
SCCA, or recurrent; the primary diagnosis of SCCA should be established using the
current World Health Organization (WHO)/International Association for the Study of
Lung Cancer (IASLC)-classification of Thoracic Malignancies; the diagnosis is based on
hematoxylin and eosin (H&E) stained slides with or without specific defined
immunohistochemistry (IHC) characteristic (p40/p63 positive, transcription termination
factor [TTF1] negative) if required for diagnosis; mixed histologies are not allowed

- Patients must either be eligible to be screened at progression on prior treatment or
to be pre-screened prior to progression on current treatment; patients will either
consent to the screening consent or the pre-screening consent, not both; these
criteria are:

- Screening at progression on prior treatment: to be eligible for screening at
progression, patients must have received at least one line of systemic therapy
for any stage of disease (stages I-IV) and must have progressed during or
following their most recent line of therapy; for patients whose prior systemic
therapy was for stage I-III disease only (i.e. patient has not received any
treatment for stage IV or recurrent disease), the prior systemic therapy must
have been a platinum-based chemotherapy regimen and disease progression on the
platinum-based chemotherapy must have occurred within one year from the last date
that patient received that therapy; for patients whose prior therapy was for
stage IV or recurrent disease, the patient must have received at least one line
of a platinum-based chemotherapy regimen or checkpoint inhibitor therapy (e.g.
nivolumab or pembrolizumab)

- Pre-screening prior to progression on current treatment: to be eligible for
pre-screening, current treatment must be for stage IV or recurrent disease and
patient must have received at least one dose of the current regimen; patients
must have previously received or currently be receiving a platinum-based
chemotherapy regimen or checkpoint inhibitor therapy (e.g. nivolumab or
pembrolizumab); patients on first-line platinum-based treatment are eligible upon
receiving cycle 1, day 1 infusion; Note: patients will not receive their
sub-study assignment until they progress and the S1400 Notice of Progression is
submitted

- Patients must have adequate tumor tissue available, defined as >= 20% tumor cells and
>= 0.2 mm^3 tumor volume

- The local interpreting pathologist must review the specimen

- The pathologist must sign the S1400 Local Pathology Review Form confirming tissue
adequacy prior to screening/pre-screening registration

- Patients must agree to have this tissue submitted to Foundation Medicine for
common broad platform Clinical Laboratory Improvement Act (CLIA) biomarker
profiling; if archival tumor material is exhausted, then a new fresh tumor biopsy
that is formalin-fixed and paraffin-embedded (FFPE) must be obtained; a tumor
block or FFPE slides 4-5 microns thick must be submitted; bone biopsies are not
allowed; if FFPE slides are to be submitted, at least 12 unstained slides plus an
H&E stained slide, or 13 unstained slides must be submitted; however it is
strongly recommended that 20 FFPE slides be submitted; Note: previous
next-generation deoxyribonucleic acid (DNA) sequencing (NGS) will be repeated if
done outside this study for sub-study assignment; patients must agree to have any
tissue that remains after NGS testing retained for the use of the translational
medicine (TM) studies (if such TM studies are defined) within any sub-study the
patient is enrolled in

- Patients must not have a known epidermal growth factor receptor (EGFR) mutation or
anaplastic lymphoma kinase (ALK) fusion; EGFR/ALK testing is not required prior to
registration and is included in the Foundation Medicine Incorporated (FMI) testing for
screening/prescreening

- Patients must have Zubrod performance status 0-1 documented within 28 days prior to
screening/pre-screening registration

- Patients must also be offered participation in banking for future use of specimens

- Patients must be willing to provide prior smoking history as required on the S1400
Onstudy Form

- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system

- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines

- SUB-STUDY REGISTRATION:

- Patients whose biomarker profiling results indicate the presence of an EGFR mutation
or echinoderm microtubule-associated protein-like 4 (EML4)/ALK fusion are not eligible

- Patients must have progressed (in the opinion of the treating investigator) following
the most recent line of therapy

- Patients must not have received any prior systemic therapy (systemic chemotherapy,
immunotherapy or investigational drug) within 21 days prior to sub-study registration;
patients must have recovered (=< grade 1) from any side effects of prior therapy;
patients must not have received any radiation therapy within 14 days prior to
sub-study registration

- Patients must have measurable disease documented by computed tomography (CT) or
magnetic resonance imaging (MRI); the CT from a combined positron emission tomography
(PET)/CT may be used to document only non-measurable disease unless it is of
diagnostic quality; measurable disease must be assessed within 28 days prior to
sub-study registration; pleural effusions, ascites and laboratory parameters are not
acceptable as the only evidence of disease; non-measurable disease must be assessed
within 42 days prior to sub-study registration; all disease must be assessed and
documented on the Baseline Tumor Assessment Form; patients whose only measurable
disease is within a previous radiation therapy port must demonstrate clearly
progressive disease (in the opinion of the treating investigator) prior to
registration

- Patients must have a CT or MRI scan of the brain to evaluate for central nervous
system (CNS) disease within 42 days prior to sub-study registration; patient must not
have leptomeningeal disease, spinal cord compression or brain metastases unless: (1)
metastases have been locally treated and have remained clinically controlled and
asymptomatic for at least 14 days following treatment and prior to registration, AND
(2) patient has no residual neurological dysfunction and has been off corticosteroids
for at least 24 hours prior to sub-study registration

- Patient must have fully recovered from the effects of prior surgery at least 14 days
prior to sub-study registration

- Patients must not be planning to receive any concurrent chemotherapy, immunotherapy,
biologic or hormonal therapy for cancer treatment; concurrent use of hormones for
non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement
therapy) is acceptable

- Absolute neutrophil count (ANC) >= 1,500/mcl obtained within 28 days prior to
sub-study registration

- Platelet count >= 100,000 mcl obtained within 28 days prior to sub-study registration

- Hemoglobin >= 9 g/dL obtained within 28 days prior to sub-study registration

- Serum bilirubin =< institutional upper limit of normal (IULN) within 28 days prior to
sub-study registration; for patients with liver metastases, bilirubin must be =< 5 x
IULN

- Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN
within 28 days prior to sub-study registration (if both ALT and AST are done, both
must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5
x IULN (if both ALT and AST are done, both must be =< 5 x IULN)

- Serum creatinine =< the IULN OR measured or calculated creatinine clearance >= 50
mL/min using the following Cockcroft-Gault Formula within 28 days prior to sub-study
registration

- Patients must have Zubrod performance status 0-1 documented within 28 days prior to
sub-study registration

- Patients must not have any grade III/IV cardiac disease as defined by the New York
Heart Association Criteria (i.e., patients with cardiac disease resulting in marked
limitation of physical activity or resulting in inability to carry on any physical
activity without discomfort), unstable angina pectoris, and myocardial infarction
within 6 months, or serious uncontrolled cardiac arrhythmia

- Patients must not have documented evidence of acute hepatitis or have an active or
uncontrolled infection

- Patients with a known history of human immunodeficiency virus (HIV) seropositivity:

- Must have undetectable viral load using standard HIV assays in clinical practice

- Must have cluster of differentiation (CD)4 count >= 400/mcL

- Must not require prophylaxis for any opportunistic infections (i.e., fungal,
Mycobacterium avium complex [mAC], or pneumocystis jiroveci pneumonia [PCP]
prophylaxis)

- Must not be newly diagnosed within 12 months prior to sub-study registration

- Prestudy history and physical exam must be obtained within 28 days prior to sub-study
registration

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for five years

- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures

- As part of the OPEN registration process the treating institution?s identity is
provided in order to ensure that the current (within 365 days) date of institutional
review board approval for this study has been entered into the system

- Patients with impaired decision-making capacity are eligible as long as their
neurological or psychological condition does not preclude their safe participation in
the study (e.g., tracking pill consumption and reporting adverse events to the
investigator)

- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines.

Study Design

Phase
Phase 2/Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
S1400A Arm I (MEDI4736) (CLOSED TO ACCRUAL 12/2015)
Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm I receive anti-B7H1 monoclonal antibody MEDI4736 IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
  • Biological: Durvalumab
    Given IV
    Other names:
    • Imfinzi
    • Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer
    • MEDI-4736
    • MEDI4736
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Active Comparator
S1400A Arm II (CLOSED TO ACCRUAL 4/2015)
Patients with tumors that do not match one of the currently active drug-biomarker combinations randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)
  • Drug: Docetaxel
    Given IV
    Other names:
    • Docecad
    • RP56976
    • Taxotere
    • Taxotere Injection Concentrate
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental
S1400A Arm III (MEDI4736)
For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12- month periods will be allowed. Patients registered to Arm III receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.
  • Biological: Durvalumab
    Given IV
    Other names:
    • Imfinzi
    • Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer
    • MEDI-4736
    • MEDI4736
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental
S1400B Arm I (taselisib) (CLOSED TO ACCRUAL 12/12/2016)
Patients with tumors positive for PI3KCA randomized to Arm I receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Drug: Taselisib
    Given PO
    Other names:
    • GDC-0032
Active Comparator
S1400B Arm II (CLOSED TO ACCRUAL 12/18/2015)
Patients with tumors positive for PI3KCA randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
  • Drug: Docetaxel
    Given IV
    Other names:
    • Docecad
    • RP56976
    • Taxotere
    • Taxotere Injection Concentrate
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental
S1400B Arm III (taselisib) (CLOSED TO ACCRUAL 12/12/2016)
Re-Registration Treatment with GDC-0032 (Taselisib). Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients will receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Drug: Taselisib
    Given PO
    Other names:
    • GDC-0032
Experimental
S1400C Arm I (palbociclib)
Patients with tumors positive for CDK4/6, CCND1, CCND2, and CCND3 randomized to Arm I receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Drug: Palbociclib
    Given PO
    Other names:
    • Ibrance
    • PD-0332991
    • PD-332991
Active Comparator
S1400C Arm II (CLOSED TO ACCRUAL 12/18/2015)
Patients with tumors positive for CDK4, CCND1, CCND2, and CCND3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
  • Drug: Docetaxel
    Given IV
    Other names:
    • Docecad
    • RP56976
    • Taxotere
    • Taxotere Injection Concentrate
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental
S1400C Arm III (palbociclib)
Re-Registration Treatment with palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients will receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Drug: Palbociclib
    Given PO
    Other names:
    • Ibrance
    • PD-0332991
    • PD-332991
Experimental
S1400D Arm I (AZD4547) (CLOSED TO ACCRUAL 04/12/2017)
Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm I receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
  • Drug: FGFR Inhibitor AZD4547
    Given PO
    Other names:
    • AZD4547
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Active Comparator
S1400D Arm II (CLOSED TO ACCRUAL 10/31/2016)
Patients with tumors positive for FGFR1, FGFR2, and FGFR3 randomized to Arm II receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)
  • Drug: Docetaxel
    Given IV
    Other names:
    • Docecad
    • RP56976
    • Taxotere
    • Taxotere Injection Concentrate
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental
S1400D Arm III (AZD4547) (CLOSED TO ACCRUAL 10/31/2016)
Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients will receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
  • Drug: FGFR Inhibitor AZD4547
    Given PO
    Other names:
    • AZD4547
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental
S1400E Arm I (CLOSED TO ACCRUAL 11/2014)
Patients with tumors positive for HGF/c-MET randomized to Arm I receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
  • Drug: Erlotinib Hydrochloride
    Given PO
    Other names:
    • Cp-358,774
    • OSI-774
    • Tarceva
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Biological: Rilotumumab
    Given IV
    Other names:
    • AMG 102
    • Anti-HGF Monoclonal Antibody AMG 102
    • Fully Human Anti-HGF Monoclonal Antibody AMG 102
Active Comparator
S1400E Arm II (CLOSED TO ACCRUAL 11/2014)
Patients with tumors positive for HGF/c-MET randomized to Arm II receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (permanently closed to accrual on 11/25/14)
  • Drug: Erlotinib Hydrochloride
    Given PO
    Other names:
    • Cp-358,774
    • OSI-774
    • Tarceva
  • Other: Laboratory Biomarker Analysis
    Correlative studies
Experimental
S1400F (durvalumab, tremelimumab)
Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.
  • Biological: Durvalumab
    Given IV
    Other names:
    • Imfinzi
    • Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer
    • MEDI-4736
    • MEDI4736
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Other: Pharmacological Study
    Correlative studies
  • Biological: Tremelimumab
    Given IV
    Other names:
    • Anti-CTLA4 Human Monoclonal Antibody CP-675,206
    • CP-675
    • CP-675,206
    • CP-675206
    • ticilimumab
Experimental
S1400G (talazoparib)
Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Other: Pharmacological Study
    Correlative studies
  • Drug: Talazoparib
    Given PO
    Other names:
    • BMN 673
    • BMN-673
Experimental
S1400I Arm I (nivolumab, ipilimumab)
Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm I receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third cycle. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
  • Biological: Ipilimumab
    Given IV
    Other names:
    • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
    • BMS-734016
    • MDX-010
    • MDX-CTLA4
    • Yervoy
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Biological: Nivolumab
    Given IV
    Other names:
    • BMS-936558
    • MDX-1106
    • NIVO
    • ONO-4538
    • Opdivo
Active Comparator
S1400I Arm II (nivolumab)
Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study randomized to Arm II receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Biological: Nivolumab
    Given IV
    Other names:
    • BMS-936558
    • MDX-1106
    • NIVO
    • ONO-4538
    • Opdivo
  • Other: Pharmacological Study
    Correlative studies

Recruiting Locations

University of Alabama at Birmingham Cancer Center
Birmingham, Alabama 35233
Contact:
Francisco Robert
protocols@swog.org

Anchorage Associates in Radiation Medicine
Anchorage, Alaska 98508
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Alaska Breast Care and Surgery LLC
Anchorage, Alaska 99508
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Alaska Oncology and Hematology LLC
Anchorage, Alaska 99508
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Anchorage Oncology Centre
Anchorage, Alaska 99508
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Katmai Oncology Group
Anchorage, Alaska 99508
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Providence Alaska Medical Center
Anchorage, Alaska 99508
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Fairbanks Memorial Hospital
Fairbanks, Alaska 99701
Contact:
John A. Keech
907-458-5380

University of Arizona Cancer Center-North Campus
Tucson, Arizona 85719
Contact:
Linda L. Garland
520-626-9008

The University of Arizona Medical Center-University Campus
Tucson, Arizona 85724
Contact:
Linda L. Garland
520-626-9008

Fowler Family Center for Cancer Care
Jonesboro, Arkansas 72401
Contact:
Carroll D. Scroggin
870-936-7000

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Konstantinos Arnaoutakis
501-686-8274

Kaiser Permanente-Anaheim
Anaheim, California 92807
Contact:
Han A. Koh
626-564-3455

Kaiser Permanente-Deer Valley Medical Center
Antioch, California 94531
Contact:
Jennifer M. Suga
510-891-3400

Sutter Auburn Faith Hospital
Auburn, California 95602
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Baldwin Park
Baldwin Park, California 91706
Contact:
Han A. Koh
626-564-3455

Kaiser Permanente-Bellflower
Bellflower, California 90706
Contact:
Han A. Koh
626-564-3455

Mills-Peninsula Medical Center
Burlingame, California 94010
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

City of Hope Comprehensive Cancer Center
Duarte, California 91010
Contact:
Marianna Koczywas
800-826-4673
becomingapatient@coh.org

Kaiser Permanente-Fontana
Fontana, California 92335
Contact:
Han A. Koh
626-564-3455

Palo Alto Medical Foundation-Fremont
Fremont, California 94538
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente - Harbor City
Harbor City, California 90710
Contact:
Han A. Koh
626-564-3455

Kaiser Permanente-Irvine
Irvine, California 92618
Contact:
Han A. Koh
626-564-3455

UC San Diego Moores Cancer Center
La Jolla, California 92093
Contact:
Lyudmila A. Bazhenova
858-822-5354
cancercto@ucsd.edu

Loma Linda University Medical Center
Loma Linda, California 92354
Contact:
Hamid R. Mirshahidi
909-558-3375

Kaiser Permanente Los Angeles Medical Center
Los Angeles, California 90027
Contact:
Han A. Koh
626-564-3455

Kaiser Permanente-Cadillac
Los Angeles, California 90034
Contact:
Han A. Koh
626-564-3455

City of Hope Mission Hills
Mission Hills, California 91345
Contact:
Marianna Koczywas
800-826-4673
becomingapatient@coh.org

Sutter Cancer Research Consortium
Novato, California 94945
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

Kaiser Permanente-Oakland
Oakland, California 94611
Contact:
Jennifer M. Suga
510-891-3400

Saint Joseph Hospital - Orange
Orange, California 92868
Contact:
Timothy E. Byun
714-734-6220

Palo Alto Medical Foundation Health Care
Palo Alto, California 94301
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

Stanford Cancer Institute Palo Alto
Palo Alto, California 94304
Contact:
Heather A. Wakelee
650-498-7061
ccto-office@stanford.edu

Kaiser Permanente - Panorama City
Panorama City, California 91402
Contact:
Han A. Koh
626-564-3455

Feather River Cancer Center
Paradise, California 95969
Contact:
Sam Mazj
530-876-7995
haleew@ah.org

Eisenhower Medical Center
Rancho Mirage, California 92270
Contact:
Constantin A. Dasanu
760-834-3798

Kaiser Permanente-Riverside
Riverside, California 92505
Contact:
Han A. Koh
626-564-3455

Sutter Roseville Medical Center
Roseville, California 95661
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

Sutter Medical Center Sacramento
Sacramento, California 95816
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

University of California Davis Comprehensive Cancer Center
Sacramento, California 95817
Contact:
David R. Gandara
916-734-3089

Saint Helena Hospital
Saint Helena, California 94574
Contact:
Gregory B. Smith
707-967-3698

Kaiser Permanente-San Diego Mission
San Diego, California 92108
Contact:
Han A. Koh
626-564-3455

Kaiser Permanente-San Diego Zion
San Diego, California 92120
Contact:
Han A. Koh
626-564-3455

Kaiser Permanente-San Marcos
San Marcos, California 92069
Contact:
Han A. Koh
626-564-3455

Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California 95065
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California 94086
Contact:
Ari D. Baron
415-209-2686
bernicl@sutterhealth.org

Northbay Cancer Center
Vacaville, California 95687
Contact:
Brian G. Vikstrom
707-624-8007

Kaiser Permanente-Vallejo
Vallejo, California 94589
Contact:
Jennifer M. Suga
510-891-3400

Kaiser Permanente-Walnut Creek
Walnut Creek, California 94596
Contact:
Jennifer M. Suga
510-891-3400

Presbyterian Intercommunity Hospital
Whittier, California 90602
Contact:
Lisa S. Wang
562-698-0811

Kaiser Permanente-Woodland Hills
Woodland Hills, California 91367
Contact:
Han A. Koh
626-564-3455

University of Colorado Hospital
Aurora, Colorado 80045
Contact:
Mark R. Hancock
720-848-0650

Penrose-Saint Francis Healthcare
Colorado Springs, Colorado 80907
Contact:
Mehmet S. Copur
501-622-2100

Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado 80907
Contact:
Mehmet S. Copur
501-622-2100

UCHealth Memorial Hospital Central
Colorado Springs, Colorado 80909
Contact:
Mark R. Hancock
720-848-0650

Kaiser Permanente-Franklin
Denver, Colorado 80205
Contact:
Alexander Menter
303-614-1300

Colorado Cancer Research Program NCORP
Denver, Colorado 80222
Contact:
Keren Sturtz
888-785-6789

Poudre Valley Hospital
Fort Collins, Colorado 80524
Contact:
Mark R. Hancock
720-848-0650

North Colorado Medical Center
Greeley, Colorado 80631
Contact:
Keren Sturtz
303-777-2663
ccrp@co-cancerresearch.org

McKee Medical Center
Loveland, Colorado 80539
Contact:
Keren Sturtz
303-777-2663
ccrp@co-cancerresearch.org

Hartford Hospital
Hartford, Connecticut 06102
Contact:
Wylie D. Hosmer
860-224-5660

Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut 06105
Contact:
Roy S. Herbst
203-785-5702

The Hospital of Central Connecticut
New Britain, Connecticut 06050
Contact:
Wylie D. Hosmer
860-224-5660

Yale University
New Haven, Connecticut 06520
Contact:
Roy S. Herbst
203-785-5702

Lawrence and Memorial Cancer Center
Waterford, Connecticut 06385
Contact:
Roy S. Herbst
860-444-3744

Veterans Affairs Connecticut Healthcare System-West Haven Campus
West Haven, Connecticut 06516
Contact:
Herta H. Chao
203-937-3421

Delaware Clinical and Laboratory Physicians PA
Newark, Delaware 19713
Contact:
Gregory A. Masters
302-733-6227

Helen F Graham Cancer Center
Newark, Delaware 19713
Contact:
Gregory A. Masters
302-733-6227

Medical Oncology Hematology Consultants PA
Newark, Delaware 19713
Contact:
Gregory A. Masters
302-733-6227

Regional Hematology and Oncology PA
Newark, Delaware 19713
Contact:
Gregory A. Masters
302-733-6227

Christiana Care Health System-Christiana Hospital
Newark, Delaware 19718
Contact:
Gregory A. Masters
302-733-6227

Beebe Health Campus
Rehoboth Beach, Delaware 19971
Contact:
Gregory A. Masters
302-733-6227

Nanticoke Memorial Hospital
Seaford, Delaware 19973
Contact:
Gregory A. Masters
302-733-6227

Christiana Care Health System-Wilmington Hospital
Wilmington, Delaware 19801
Contact:
Gregory A. Masters
302-733-6227

Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida 33180
Contact:
Michael A. Schwartz
888-823-5923
ctsucontact@westat.com

Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida 33021
Contact:
Robert A. Hirsch
954-265-4325

Mount Sinai Medical Center
Miami Beach, Florida 33140
Contact:
Michael A. Schwartz
305-674-2625
info@msccop.com

Memorial Hospital West
Pembroke Pines, Florida 33028
Contact:
Robert A. Hirsch
954-265-4325

Moffitt Cancer Center
Tampa, Florida 33612
Contact:
Jhanelle E. Gray
800-456-7121
canceranswers@moffitt.org

Phoebe Putney Memorial Hospital
Albany, Georgia 31701
Contact:
Sharad A. Ghamande
706-721-1663
cancer@augusta.edu

Emory University Hospital Midtown
Atlanta, Georgia 30308
Contact:
Taofeek K. Owonikoko
404-489-9164

Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
Contact:
Taofeek K. Owonikoko
404-489-9164

Emory Saint Joseph's Hospital
Atlanta, Georgia 30342
Contact:
Taofeek K. Owonikoko
404-489-9164

Northside Hospital
Atlanta, Georgia 30342
Contact:
Sreekanth C. Reddy
404-303-3355

John B Amos Cancer Center
Columbus, Georgia 31904
Contact:
Andrew W. Pippas
706-660-6404

Dekalb Medical Center
Decatur, Georgia 30033
Contact:
Sharad A. Ghamande
706-721-1663
cancer@augusta.edu

Northeast Georgia Medical Center-Gainesville
Gainesville, Georgia 30501
Contact:
Charles H. Nash
770-219-8800
cancerpatient.navigator@nghs.com

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia 31405
Contact:
Howard A. Zaren
912-819-5704

South Georgia Medical Center/Pearlman Cancer Center
Valdosta, Georgia 31602
Contact:
Samuel N. Ofori
229-259-4628
maryann.heddon@sgmc.org

Hawaii Oncology Inc-Pali Momi
'Aiea, Hawaii 96701
Contact:
Jeffrey L. Berenberg
808-586-2979

Pali Momi Medical Center
'Aiea, Hawaii 96701
Contact:
Jeffrey L. Berenberg
808-586-2979

Hawaii Cancer Care Inc-POB II
Honolulu, Hawaii 96813
Contact:
Jeffrey L. Berenberg
808-586-2979

Hawaii Oncology Inc-POB I
Honolulu, Hawaii 96813
Contact:
Jeffrey L. Berenberg
808-586-2979

Queen's Medical Center
Honolulu, Hawaii 96813
Contact:
Jeffrey L. Berenberg
808-586-2979

Straub Clinic and Hospital
Honolulu, Hawaii 96813
Contact:
Jeffrey L. Berenberg
808-586-2979

University of Hawaii Cancer Center
Honolulu, Hawaii 96813
Contact:
Jeffrey L. Berenberg
808-586-2979

Hawaii Cancer Care Inc-Liliha
Honolulu, Hawaii 96817
Contact:
Jeffrey L. Berenberg
808-586-2979

Hawaii Oncology Inc-Kuakini
Honolulu, Hawaii 96817
Contact:
Jeffrey L. Berenberg
808-586-2979

Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii 96819
Contact:
Jennifer M. Suga
808-432-5195

Kapiolani Medical Center for Women and Children
Honolulu, Hawaii 96826
Contact:
Jeffrey L. Berenberg
808-586-2979

Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho 83706
Contact:
Philip J. Stella
208-367-7954

Saint Luke's Mountain States Tumor Institute
Boise, Idaho 83712
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Kootenai Medical Center
Coeur d'Alene, Idaho 83814
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho 83619
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho 83642
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Saint Luke's Mountain States Tumor Institute - Nampa
Nampa, Idaho 83686
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Kootenai Cancer Center
Post Falls, Idaho 83854
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Kootenai Cancer Clinic
Sandpoint, Idaho 83864
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Saint Luke's Mountain States Tumor Institute-Twin Falls
Twin Falls, Idaho 83301
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Illinois CancerCare-Bloomington
Bloomington, Illinois 61704
Contact:
James L. Wade
309-243-3605

Illinois CancerCare-Canton
Canton, Illinois 61520
Contact:
James L. Wade
309-243-3605

Illinois CancerCare-Carthage
Carthage, Illinois 62321
Contact:
James L. Wade
309-243-3605

Centralia Oncology Clinic
Centralia, Illinois 62801
Contact:
James L. Wade
309-243-3605

Northwestern University
Chicago, Illinois 60611
Contact:
Young K. Chae
312-695-1301
cancer@northwestern.edu

Carle on Vermilion
Danville, Illinois 61832
Contact:
Yujie Zhao
630-978-6212
Cancer.Research@rushcopley.com

Cancer Care Specialists of Central Illinois
Decatur, Illinois 62526
Contact:
James L. Wade
309-243-3605

Decatur Memorial Hospital
Decatur, Illinois 62526
Contact:
James L. Wade
309-243-3605

Carle Physician Group-Effingham
Effingham, Illinois 62401
Contact:
Yujie Zhao
630-978-6212
Cancer.Research@rushcopley.com

Crossroads Cancer Center
Effingham, Illinois 62401
Contact:
James L. Wade
309-243-3605

AMITA Health Alexian Brothers Medical Center
Elk Grove Village, Illinois 60007
Contact:
Bruce B. Bank
847-952-7164
fredianc@alexian.net

Illinois CancerCare-Eureka
Eureka, Illinois 61530
Contact:
James L. Wade
309-243-3605

NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois 60201
Contact:
Thomas A. Hensing
847-570-2109

Illinois CancerCare-Galesburg
Galesburg, Illinois 61401
Contact:
James L. Wade
309-243-3605

NorthShore University HealthSystem-Glenbrook Hospital
Glenview, Illinois 60026
Contact:
Thomas A. Hensing
847-570-2109

Ingalls Memorial Hospital
Harvey, Illinois 60426
Contact:
Mark F. Kozloff
773-834-7424

NorthShore University HealthSystem-Highland Park Hospital
Highland Park, Illinois 60035
Contact:
Thomas A. Hensing
847-570-2109

AMITA Health Cancer Institute and Outpatient Center
Hinsdale, Illinois 60521
Contact:
Bruce B. Bank
847-952-7164
fredianc@alexian.net

Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois 61443
Contact:
James L. Wade
309-243-3605

Illinois CancerCare-Macomb
Macomb, Illinois 61455
Contact:
James L. Wade
309-243-3605

Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois 61938
Contact:
Yujie Zhao
630-978-6212
Cancer.Research@rushcopley.com

Loyola University Medical Center
Maywood, Illinois 60153
Contact:
Kathy S. Albain
708-226-4357

AMG Oncology - Naperville
Naperville, Illinois 60540
Contact:
Fariborze B. Barhamand
630-369-1501

UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois 60451
Contact:
Everett E. Vokes
773-834-7424

University of Chicago Medicine-Orland Park
Orland Park, Illinois 60462
Contact:
Everett E. Vokes
773-834-7424

Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois 61350
Contact:
James L. Wade
309-243-3605

Illinois CancerCare-Pekin
Pekin, Illinois 61554
Contact:
James L. Wade
309-243-3605

Illinois CancerCare-Peoria
Peoria, Illinois 61615
Contact:
James L. Wade
309-243-3605

Illinois CancerCare-Peru
Peru, Illinois 61354
Contact:
James L. Wade
309-243-3605

Illinois CancerCare-Princeton
Princeton, Illinois 61356
Contact:
James L. Wade
309-243-3605

Southern Illinois University School of Medicine
Springfield, Illinois 62702
Contact:
James L. Wade
309-243-3605

Springfield Clinic
Springfield, Illinois 62702
Contact:
James L. Wade
309-243-3605

Memorial Medical Center
Springfield, Illinois 62781
Contact:
James L. Wade
309-243-3605

Cancer Care Specialists of Illinois-Swansea
Swansea, Illinois 62226
Contact:
James L. Wade
309-243-3605

Carle Cancer Center
Urbana, Illinois 61801
Contact:
Yujie Zhao
630-978-6212
Cancer.Research@rushcopley.com

The Carle Foundation Hospital
Urbana, Illinois 61801
Contact:
Yujie Zhao
630-978-6212
Cancer.Research@rushcopley.com

IU Health North Hospital
Carmel, Indiana 46032
Contact:
Shadia I. Jalal
888-342-7602

Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana 46202
Contact:
Shadia I. Jalal
888-342-7602

IU Health Methodist Hospital
Indianapolis, Indiana 46202
Contact:
Shadia I. Jalal
888-342-7602

Richard L. Roudebush Veterans Affairs Medical Center
Indianapolis, Indiana 46202
Contact:
Shadia I. Jalal
888-342-7602

Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana 46202
Contact:
Shadia I. Jalal
317-630-7808

Franciscan Health Indianapolis
Indianapolis, Indiana 46237
Contact:
Stephen E. Rubenstein
317-528-7060

Memorial Regional Cancer Center Day Road
Mishawaka, Indiana 46545
Contact:
Thomas J. Reid
800-284-7370

Franciscan Health Mooresville
Mooresville, Indiana 46158
Contact:
Stephen E. Rubenstein
317-528-7060

The Community Hospital
Munster, Indiana 46321
Contact:
Mohamad Kassar
219-836-3349

Reid Health
Richmond, Indiana 47374
Contact:
Howard M. Gross
937-775-1350
som_dcop@wright.edu

Memorial Hospital of South Bend
South Bend, Indiana 46601
Contact:
Thomas J. Reid
800-284-7370

Northern Indiana Cancer Research Consortium
South Bend, Indiana 46628
Contact:
Robin T. Zon
574-234-5123

Union Hospital
Terre Haute, Indiana 47804
Contact:
Stephen E. Rubenstein
317-528-7060

Mary Greeley Medical Center
Ames, Iowa 50010
Contact:
Joseph J. Merchant
515-239-2621

McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa 50010
Contact:
Joseph J. Merchant
515-239-2621

University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa 52722
Contact:
Muhammad Furqan
563-355-7733
kedaprile@rccqc.com

McFarland Clinic PC-Boone
Boone, Iowa 50036
Contact:
Joseph J. Merchant
515-239-2621

Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa 50325
Contact:
Mehmet S. Copur
501-622-2100

Mercy Cancer Center-West Lakes
Clive, Iowa 50325
Contact:
Mehmet S. Copur
501-622-2100

Greater Regional Medical Center
Creston, Iowa 50801
Contact:
Mehmet S. Copur
501-622-2100

Genesis Medical Center - East Campus
Davenport, Iowa 52803
Contact:
George Kovach
800-446-6088
werners@genesishealth.com

Iowa Methodist Medical Center
Des Moines, Iowa 50309
Contact:
Robert J. Behrens
515-239-2621

Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa 50309
Contact:
Robert J. Behrens
515-282-2921

Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa 50309
Contact:
Robert J. Behrens
515-239-2621

Broadlawns Medical Center
Des Moines, Iowa 50314
Contact:
Robert J. Behrens
888-823-5923
ctsucontact@westat.com

Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa 50314
Contact:
Mehmet S. Copur
501-622-2100

Mercy Medical Center - Des Moines
Des Moines, Iowa 50314
Contact:
Mehmet S. Copur
501-622-2100

Iowa Lutheran Hospital
Des Moines, Iowa 50316
Contact:
Robert J. Behrens
515-239-2621

McFarland Clinic PC-Trinity Cancer Center
Fort Dodge, Iowa 50501
Contact:
Joseph J. Merchant
515-239-2621

University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa 52242
Contact:
Muhammad Furqan
800-237-1225

McFarland Clinic PC-Jefferson
Jefferson, Iowa 50129
Contact:
Joseph J. Merchant
515-239-2621

McFarland Clinic PC-Marshalltown
Marshalltown, Iowa 50158
Contact:
Joseph J. Merchant
515-239-2621

Siouxland Regional Cancer Center
Sioux City, Iowa 51101
Contact:
Donald B. Wender
712-252-0088

Methodist West Hospital
West Des Moines, Iowa 50266-7700
Contact:
Robert J. Behrens
515-239-2621

Mercy Medical Center-West Lakes
West Des Moines, Iowa 50266
Contact:
Mehmet S. Copur
501-622-2100

Cancer Center of Kansas - Chanute
Chanute, Kansas 66720
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas - Dodge City
Dodge City, Kansas 67801
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas - El Dorado
El Dorado, Kansas 67042
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas 66701
Contact:
Shaker R. Dakhil
316-268-5374

Central Care Cancer Center - Great Bend
Great Bend, Kansas 67530
Contact:
Chao H. Huang
913-948-5588
aroland@kccop.org

Hays Medical Center
Hays, Kansas 67601
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Cancer Center of Kansas-Independence
Independence, Kansas 67301
Contact:
Shaker R. Dakhil
316-268-5374

University of Kansas Cancer Center-West
Kansas City, Kansas 66112
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

University of Kansas Cancer Center
Kansas City, Kansas 66160
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Cancer Center of Kansas-Kingman
Kingman, Kansas 67068
Contact:
Shaker R. Dakhil
316-268-5374

Lawrence Memorial Hospital
Lawrence, Kansas 66044
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas-Liberal
Liberal, Kansas 67905
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas-Manhattan
Manhattan, Kansas 66502
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas - McPherson
McPherson, Kansas 67460
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas - Newton
Newton, Kansas 67114
Contact:
Shaker R. Dakhil
316-268-5374

Olathe Medical Center
Olathe, Kansas 66061
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

University of Kansas Cancer Center-Overland Park
Overland Park, Kansas 66210
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Cancer Center of Kansas - Parsons
Parsons, Kansas 67357
Contact:
Shaker R. Dakhil
316-268-5374

Via Christi Hospital-Pittsburg
Pittsburg, Kansas 66762
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Kansas City NCI Community Oncology Research Program
Prairie Village, Kansas 66208
Contact:
Rakesh Gaur
913-948-5588
aroland@kccop.org

Cancer Center of Kansas - Pratt
Pratt, Kansas 67124
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas - Salina
Salina, Kansas 67401
Contact:
Shaker R. Dakhil
316-268-5374

Salina Regional Health Center
Salina, Kansas 67401
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Cotton O'Neil Cancer Center / Stormont Vail Health
Topeka, Kansas 66606
Contact:
David E. Einspahr
protocols@swog.org

Saint Francis Hospital and Medical Center - Topeka
Topeka, Kansas 66606
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Cancer Center of Kansas - Wellington
Wellington, Kansas 67152
Contact:
Shaker R. Dakhil
316-268-5374

University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas 66205
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas 67208
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas - Wichita
Wichita, Kansas 67214
Contact:
Shaker R. Dakhil
316-268-5374

Via Christi Regional Medical Center
Wichita, Kansas 67214
Contact:
Shaker R. Dakhil
316-268-5374

Wichita NCI Community Oncology Research Program
Wichita, Kansas 67214
Contact:
Shaker R. Dakhil
316-268-5374

Cancer Center of Kansas - Winfield
Winfield, Kansas 67156
Contact:
Shaker R. Dakhil
316-268-5374

King's Daughter's Medical Center
Ashland, Kentucky 41101
Contact:
David K. Goebel
888-823-5923
ctsucontact@westat.com

Flaget Memorial Hospital
Bardstown, Kentucky 40004
Contact:
Mehmet S. Copur
501-622-2100

Baptist Health Corbin
Corbin, Kentucky 40701
Contact:
Firas B. Badin
859-260-6425

Hardin Memorial Hospital
Elizabethtown, Kentucky 42701
Contact:
Chandler H. Park
859-260-6456
micheal.stephens@BHSI.com

Baptist Health Lexington
Lexington, Kentucky 40503
Contact:
Firas B. Badin
859-260-6425

Saint Joseph Hospital East
Lexington, Kentucky 40509
Contact:
Mehmet S. Copur
859-967-5107

University of Kentucky/Markey Cancer Center
Lexington, Kentucky 40536
Contact:
Susanne M. Arnold
859-257-3379

Baptist Health Louisville
Louisville, Kentucky 40207
Contact:
Firas B. Badin
859-260-6425

Baptist Health Madisonville/Merle Mahr Cancer Center
Madisonville, Kentucky 42431
Contact:
Firas B. Badin
859-260-6425

Baptist Health Paducah
Paducah, Kentucky 42003
Contact:
Firas B. Badin
859-260-6425

LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana 70805
Contact:
Augusto C. Ochoa
504-568-2428
emede1@lsuhsc.edu

Louisiana Hematology Oncology Associates LLC
Baton Rouge, Louisiana 70809
Contact:
Augusto C. Ochoa
504-568-2428
emede1@lsuhsc.edu

Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana 70809
Contact:
Augusto C. Ochoa
504-568-2428
emede1@lsuhsc.edu

Ochsner Health Center-Summa
Baton Rouge, Louisiana 70809
Contact:
Marc R. Matrana
504-842-3708

Our Lady of the Lake Physicians Group - Medical Oncology
Baton Rouge, Louisiana 70809
Contact:
Augusto C. Ochoa
504-568-2428
emede1@lsuhsc.edu

Medical Center of Baton Rouge
Baton Rouge, Louisiana 70816
Contact:
Marc R. Matrana
225-761-5346
Camille.Beck@Ochsner.org

Northshore Oncology Associates-Covington
Covington, Louisiana 70433
Contact:
David S. Hanson
225-215-1353
clinicalresearch@marybird.com

Oncology Center of The South Incorporated
Houma, Louisiana 70360
Contact:
David S. Hanson
225-215-1353
clinicalresearch@marybird.com

East Jefferson General Hospital
Metairie, Louisiana 70006
Contact:
Augusto C. Ochoa
504-568-2428
emede1@lsuhsc.edu

Robert Veith MD LLC
Metairie, Louisiana 70006
Contact:
Augusto C. Ochoa
504-568-2428
emede1@lsuhsc.edu

University Medical Center New Orleans
New Orleans, Louisiana 70112
Contact:
Augusto C. Ochoa
504-568-2428
emede1@lsuhsc.edu

LSU Healthcare Network/Saint Charles
New Orleans, Louisiana 70115
Contact:
Augusto C. Ochoa
504-568-2428
emede1@lsuhsc.edu

Ochsner Medical Center Jefferson
New Orleans, Louisiana 70121
Contact:
Marc R. Matrana
504-842-3708

Harold Alfond Center for Cancer Care
Augusta, Maine 04330
Contact:
Thomas H. Openshaw
207-973-4274

Eastern Maine Medical Center
Bangor, Maine 04401
Contact:
Thomas H. Openshaw
207-973-4274

Lafayette Family Cancer Center-EMMC
Brewer, Maine 04412
Contact:
Thomas H. Openshaw
207-973-4274

University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland 21201
Contact:
Katherine A. Scilla
800-888-8823

Greater Baltimore Medical Center
Baltimore, Maryland 21204
Contact:
Mei Tang
443-849-3706

Sinai Hospital of Baltimore
Baltimore, Maryland 21215
Contact:
Roberto F. Martinez
410-601-6120
pridgely@lifebridgehealth.org

Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland 21287
Contact:
Julie R. Brahmer
410-955-8804
jhcccro@jhmi.edu

Western Maryland Regional Medical Center
Cumberland, Maryland 21502
Contact:
Blanche H. Mavromatis
240-964-1400

Northwest Hospital Center
Randallstown, Maryland 21133
Contact:
Roberto F. Martinez
410-601-6120
pridgely@lifebridgehealth.org

Peninsula Regional Medical Center
Salisbury, Maryland 21801
Contact:
Justinian R. Ngaiza
866-922-6237

William E Kahlert Regional Cancer Center/Sinai Hospital
Westminster, Maryland 21157
Contact:
Roberto F. Martinez
410-601-6120
pridgely@lifebridgehealth.org

Beverly Hospital
Beverly, Massachusetts 01915
Contact:
Shakeeb A. Yunus
978-922-3000

Boston Medical Center
Boston, Massachusetts 02118
Contact:
Marjory Charlot
617-638-8265

Lahey Hospital and Medical Center
Burlington, Massachusetts 01805
Contact:
Paul J. Hesketh
781-744-8027

Simonds-Sinon Regional Cancer Center
Fitchburg, Massachusetts 01420
Contact:
William V. Walsh
508-856-3216
cancer.research@umassmed.edu

Addison Gilbert Hospital
Gloucester, Massachusetts 01930
Contact:
Shakeeb A. Yunus
978-283-4000

Baystate Medical Center
Springfield, Massachusetts 01199
Contact:
John C. McCann
413-794-3565
tamara.wrenn@baystatehealth.org

University of Massachusetts Medical School
Worcester, Massachusetts 01655
Contact:
William V. Walsh
508-856-3216
cancer.research@umassmed.edu

Saint Joseph Mercy Hospital
Ann Arbor, Michigan 48106
Contact:
Philip J. Stella
208-367-7954

University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan 48109
Contact:
Gregory P. Kalemkerian
800-865-1125

Bronson Battle Creek
Battle Creek, Michigan 49017
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

IHA Hematology Oncology Consultants-Brighton
Brighton, Michigan 48114
Contact:
Philip J. Stella
208-367-7954

Saint Joseph Mercy Brighton
Brighton, Michigan 48114
Contact:
Philip J. Stella
208-367-7954

Henry Ford Cancer Institute?Downriver
Brownstown, Michigan 48183
Contact:
Ding Wang
888-823-5923
ctsucontact@westat.com

IHA Hematology Oncology Consultants-Canton
Canton, Michigan 48188
Contact:
Philip J. Stella
208-367-7954

Saint Joseph Mercy Canton
Canton, Michigan 48188
Contact:
Philip J. Stella
208-367-7954

IHA Hematology Oncology Consultants-Chelsea
Chelsea, Michigan 48118
Contact:
Philip J. Stella
208-367-7954

Saint Joseph Mercy Chelsea
Chelsea, Michigan 48118
Contact:
Philip J. Stella
208-367-7954

Hematology Oncology Consultants-Clarkston
Clarkston, Michigan 48346
Contact:
Philip J. Stella
208-367-7954

Newland Medical Associates-Clarkston
Clarkston, Michigan 48346
Contact:
Philip J. Stella
208-367-7954

Henry Ford Macomb Hospital-Clinton Township
Clinton Township, Michigan 48038
Contact:
Ding Wang
313-916-1784

Henry Ford Medical Center-Fairlane
Dearborn, Michigan 48126
Contact:
Ding Wang
888-734-5322

Wayne State University/Karmanos Cancer Institute
Detroit, Michigan 48201
Contact:
Antoinette J. Wozniak
313-576-9363

Henry Ford Hospital
Detroit, Michigan 48202
Contact:
Ding Wang
313-916-1784

Saint John Hospital and Medical Center
Detroit, Michigan 48236
Contact:
Philip J. Stella
208-367-7954

Green Bay Oncology - Escanaba
Escanaba, Michigan 49829
Contact:
Matthew L. Ryan
920-433-8889
Christy.Gilchrist@hshs.org

Weisberg Cancer Treatment Center
Farmington Hills, Michigan 48334
Contact:
Antoinette J. Wozniak
313-576-9363

Genesys Hurley Cancer Institute
Flint, Michigan 48503
Contact:
Philip J. Stella
208-367-7954

Hurley Medical Center
Flint, Michigan 48503
Contact:
Philip J. Stella
208-367-7954

Mercy Health Saint Mary's
Grand Rapids, Michigan 49503
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

Spectrum Health at Butterworth Campus
Grand Rapids, Michigan 49503
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

West Michigan Cancer Center
Kalamazoo, Michigan 49007
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

Sparrow Hospital
Lansing, Michigan 48912
Contact:
Philip J. Stella
208-367-7954

Saint Mary Mercy Hospital
Livonia, Michigan 48154
Contact:
Philip J. Stella
208-367-7954

Monroe Cancer Center
Monroe, Michigan 48162
Contact:
Abhijit B. Saste
419-824-1842

Lakeland Community Hospital
Niles, Michigan 49120
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

Assarian Cancer Center
Novi, Michigan 48374-1236
Contact:
Michael J. Kraut
248-849-5337
jaswinder.grewal@stjohn.org

Henry Ford Medical Center-Columbus
Novi, Michigan 48377
Contact:
Ding Wang
888-734-5322

Hope Cancer Center
Pontiac, Michigan 48341
Contact:
Philip J. Stella
208-367-7954

Newland Medical Associates-Pontiac
Pontiac, Michigan 48341
Contact:
Philip J. Stella
208-367-7954

Saint Joseph Mercy Oakland
Pontiac, Michigan 48341
Contact:
Philip J. Stella
208-367-7954

Spectrum Health Reed City Hospital
Reed City, Michigan 49677
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

William Beaumont Hospital-Royal Oak
Royal Oak, Michigan 48073
Contact:
Michael J. Stender
248-551-7695

Saint Mary's of Michigan
Saginaw, Michigan 48601
Contact:
Philip J. Stella
208-367-7954

Lakeland Hospital
Saint Joseph, Michigan 49085
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

Marie Yeager Cancer Center
Saint Joseph, Michigan 49085
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

Providence Hospital-Southfield Cancer Center
Southfield, Michigan 48075
Contact:
Michael J. Kraut
248-849-5337
jaswinder.grewal@stjohn.org

Munson Medical Center
Traverse City, Michigan 49684
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

William Beaumont Hospital - Troy
Troy, Michigan 48098
Contact:
Michael J. Stender
248-551-7695

Saint John Macomb-Oakland Hospital
Warren, Michigan 48093
Contact:
Philip J. Stella
208-367-7954

Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan 48322
Contact:
Ding Wang
888-734-5322

Metro Health Hospital
Wyoming, Michigan 49519
Contact:
Kathleen J. Yost
616-391-1230
crcwm-regulatory@crcwm.org

IHA Hematology Oncology Consultants-Ann Arbor
Ypsilanti, Michigan 48197
Contact:
Philip J. Stella
208-367-7954

Sanford Clinic North-Bemidgi
Bemidji, Minnesota 56601
Contact:
Preston D. Steen
712-252-0088

Mercy Hospital
Coon Rapids, Minnesota 55433
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

Essentia Health Cancer Center
Duluth, Minnesota 55805
Contact:
Bret E. Friday
888-203-7267

Fairview-Southdale Hospital
Edina, Minnesota 55435
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

Unity Hospital
Fridley, Minnesota 55432
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

Saint John's Hospital - Healtheast
Maplewood, Minnesota 55109
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

Abbott-Northwestern Hospital
Minneapolis, Minnesota 55407
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

Hennepin County Medical Center
Minneapolis, Minnesota 55415
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

North Memorial Medical Health Center
Robbinsdale, Minnesota 55422
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota 55416
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

Rice Memorial Hospital
Willmar, Minnesota 56201
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota 55125
Contact:
David M. King
952-993-1517
mmcorc@healthpartners.com

University of Mississippi Medical Center
Jackson, Mississippi 39216
Contact:
John C. Henegan
601-815-6700

Baptist Memorial Hospital and Cancer Center-Oxford
Oxford, Mississippi 38655
Contact:
Raymond U. Osarogiagbon
870-936-7000

Singing River Hospital
Pascagoula, Mississippi 39581
Contact:
James E. Clarkson
228-809-5292

Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven, Mississippi 38671
Contact:
Raymond U. Osarogiagbon
870-936-7000

Parkland Health Center-Bonne Terre
Bonne Terre, Missouri 63628
Contact:
James L. Wade
309-243-3605

Saint Francis Medical Center
Cape Girardeau, Missouri 63703
Contact:
James L. Wade
309-243-3605

Southeast Cancer Center
Cape Girardeau, Missouri 63703
Contact:
James L. Wade
309-243-3605

Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri 63141
Contact:
Daniel Morgensztern
800-600-3606
info@siteman.wustl.edu

Capital Region Medical Center-Goldschmidt Cancer Center
Jefferson City, Missouri 65109
Contact:
James L. Wade
309-243-3605

Mercy Hospital Joplin
Joplin, Missouri 64804
Contact:
Jay W. Carlson
888-221-4849

Truman Medical Center
Kansas City, Missouri 64108
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Kansas City Veterans Affairs Medical Center
Kansas City, Missouri 64128
Contact:
Chao H. Huang
800-525-1483

The University of Kansas Cancer Center-South
Kansas City, Missouri 64131
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

The University of Kansas Cancer Center-North
Kansas City, Missouri 64154
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

The University of Kansas Cancer Center-Lee's Summit
Lee's Summit, Missouri 64064
Contact:
Chao H. Huang
913-945-7552
ctnursenav@kumc.edu

Washington University School of Medicine
Saint Louis, Missouri 63110
Contact:
Daniel Morgensztern
800-600-3606
info@siteman.wustl.edu

Missouri Baptist Medical Center
Saint Louis, Missouri 63131
Contact:
James L. Wade
309-243-3605

Mercy Hospital Saint Louis
Saint Louis, Missouri 63141
Contact:
Jay W. Carlson
888-221-4849

Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri 63376
Contact:
Daniel Morgensztern
800-600-3606
info@siteman.wustl.edu

Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
Contact:
James L. Wade
309-243-3605

Mercy Hospital Springfield
Springfield, Missouri 65804
Contact:
Jay W. Carlson
888-221-4849

CoxHealth South Hospital
Springfield, Missouri 65807
Contact:
Jay W. Carlson
888-221-4849

Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
Contact:
James L. Wade
309-243-3605

Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri 63127
Contact:
James L. Wade
309-243-3605

Community Hospital of Anaconda
Anaconda, Montana 59711
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Billings Clinic Cancer Center
Billings, Montana 59101
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Montana Cancer Consortium NCORP
Billings, Montana 59102
Contact:
Benjamin T. Marchello
800-648-6274

Bozeman Deaconess Hospital
Bozeman, Montana 59715
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana 59405
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Great Falls Clinic
Great Falls, Montana 59405
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Saint Peter's Community Hospital
Helena, Montana 59601
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Kalispell Regional Medical Center
Kalispell, Montana 59901
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

Community Medical Hospital
Missoula, Montana 59804
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

CHI Health Saint Francis
Grand Island, Nebraska 68803
Contact:
Mehmet S. Copur
501-622-2100

Nebraska Hematology and Oncology
Lincoln, Nebraska 68506
Contact:
Gamini S. Soori
402-991-8070
mwilwerding@mvcc.cc

Southeast Nebraska Cancer Center
Lincoln, Nebraska 68510
Contact:
Gamini S. Soori
402-991-8070
mwilwerding@mvcc.cc

Faith Regional Health Services Carson Cancer Center
Norfolk, Nebraska 68701
Contact:
Gamini S. Soori
402-991-8070
mwilwerding@mvcc.cc

Great Plains Health Callahan Cancer Center
North Platte, Nebraska 69101
Contact:
Gamini S. Soori
402-991-0070
mwilwerding@canceralliance-ne.org

Missouri Valley Cancer Consortium
Omaha, Nebraska 68106
Contact:
Gamini S. Soori
402-398-6060

Nebraska Cancer Specialists - Omaha
Omaha, Nebraska 68124
Contact:
Gamini S. Soori
402-991-8070
mwilwerding@mvcc.cc

University of Nebraska Medical Center
Omaha, Nebraska 68198
Contact:
Apar K. Ganti
402-559-6941
unmcrsa@unmc.edu

Regional West Medical Center Cancer Center
Scottsbluff, Nebraska 69361
Contact:
Gamini S. Soori
402-991-8070
mwilwerding@mvcc.cc

Nevada Cancer Research Foundation CCOP
Las Vegas, Nevada 89106
Contact:
John A. Ellerton
702-384-0013

Renown Regional Medical Center
Reno, Nevada 89502
Contact:
John A. Ellerton
702-384-0013

New Hampshire Oncology Hematology PA-Concord
Concord, New Hampshire 03301
Contact:
Douglas J. Weckstein
603-663-1800

New Hampshire Oncology Hematology PA-Hooksett
Hooksett, New Hampshire 03106
Contact:
Douglas J. Weckstein
603-663-1800

Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire 03756
Contact:
Konstantin H. Dragnev
800-639-6918
cancer.research.nurse@dartmouth.edu

Norris Cotton Cancer Center-Manchester
Manchester, New Hampshire 03102
Contact:
Konstantin H. Dragnev
800-639-6918
cancer.research.nurse@dartmouth.edu

The Valley Hospital-Luckow Pavilion
Paramus, New Jersey 07652
Contact:
Jin S. Lee
201-634-5792

Valley Hospital
Ridgewood, New Jersey 07450
Contact:
Jin S. Lee
201-634-5792
cparish@valleyhealth.com

Robert Wood Johnson University Hospital Somerset
Somerville, New Jersey 08876
Contact:
Steven E. Young
908-685-2481

Valley Health System-Hematology/Oncology
Westwood, New Jersey 07675
Contact:
Jin S. Lee
888-823-5923
ctsucontact@westat.com

Lovelace Medical Center-Saint Joseph Square
Albuquerque, New Mexico 87102
Contact:
Ian Rabinowitz
505-272-0530
AYost@nmcca.org

University of New Mexico Cancer Center
Albuquerque, New Mexico 87102
Contact:
Ian Rabinowitz
505-925-0366
LByatt@nmcca.org

New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico 87109
Contact:
Ian Rabinowitz
505-925-0366
LByatt@nmcca.org

Memorial Medical Center - Las Cruces
Las Cruces, New Mexico 88011
Contact:
Ian Rabinowitz
505-925-0366
LByatt@nmcca.org

New York Oncology Hematology PC -Albany Medical Center
Albany, New York 12208
Contact:
Makenzi C. Evangelist
518-489-3612
gerryann.currier@usoncology.com

Montefiore Medical Center-Einstein Campus
Bronx, New York 10461
Contact:
Haiying Cheng
718-904-2730
aecc@aecom.yu.edu

Montefiore Medical Center-Weiler Hospital
Bronx, New York 10461
Contact:
Haiying Cheng
718-904-2730
aecc@aecom.yu.edu

Montefiore Medical Center - Moses Campus
Bronx, New York 10467
Contact:
Haiying Cheng
718-904-2730
aecc@aecom.yu.edu

New York-Presbyterian/Brooklyn Methodist Hospital
Brooklyn, New York 11215
Contact:
Andy Y. Huang
718-780-3677
Adg9003@nyp.org

Roswell Park Cancer Institute
Buffalo, New York 14263
Contact:
Hongbin Chen
877-275-7724

Mary Imogene Bassett Hospital
Cooperstown, New York 13326
Contact:
Eric Bravin
607-547-3073
diana.crean@bassett.org

Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York 14905
Contact:
Serge Dauphin
607-271-7000

Columbia University/Herbert Irving Cancer Center
New York, New York 10032
Contact:
Naiyer A. Rizvi
212-639-7202

University of Rochester
Rochester, New York 14642
Contact:
Paul M. Barr
585-275-5830

State University of New York Upstate Medical University
Syracuse, New York 13210
Contact:
Stephen L. Graziano
315-464-5476

Faxton-Saint Luke's Healthcare
Utica, New York 13502
Contact:
Atul V. Butala
888-823-5923
ctsucontact@westat.com

Randolph Hospital
Asheboro, North Carolina 27203
Contact:
Vinay K. Gudena
336-832-0821

Mission Hospital-Memorial Campus
Asheville, North Carolina 28801
Contact:
Christopher H. Chay
828-213-4150

Cone Health Cancer Center at Alamance Regional
Burlington, North Carolina 27215
Contact:
Vinay K. Gudena
336-832-0821

Novant Health Presbyterian Medical Center
Charlotte, North Carolina 28204
Contact:
Nasfat Shehadeh
704-384-5369
nnechiporchik@novanthealth.org

Oncology Specialists of Charlotte
Charlotte, North Carolina 28207
Contact:
Nasfat Shehadeh
704-384-8920
nnechiporchik@novanthealth.org

Southern Oncology Specialists-Charlotte
Charlotte, North Carolina 28262
Contact:
Nasfat Shehadeh
704-384-8920
nnechiporchik@novanthealth.org

Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina 28328
Contact:
James N. Atkins
252-399-7491

Duke University Medical Center
Durham, North Carolina 27710
Contact:
Jeffrey Crawford
888-275-3853

Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina 27534
Contact:
James N. Atkins
252-399-7491

Wayne Memorial Hospital
Goldsboro, North Carolina 27534
Contact:
James N. Atkins
252-399-7491

Cone Health Cancer Center
Greensboro, North Carolina 27403
Contact:
Vinay K. Gudena
336-832-0821

Lake Norman Hematology Oncology Specialists-Huntersville
Huntersville, North Carolina 28078
Contact:
Nasfat Shehadeh
704-384-8920
nnechiporchik@novanthealth.org

Southern Oncology Specialists-Huntersville
Huntersville, North Carolina 28078
Contact:
Nasfat Shehadeh
704-384-8920
nnechiporchik@novanthealth.org

Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina 28546
Contact:
James N. Atkins
252-399-7491

Kinston Medical Specialists PA
Kinston, North Carolina 28501
Contact:
Peter R. Watson
252-559-2200

Matthews Radiation Oncology Center
Matthews, North Carolina 28105
Contact:
Nasfat Shehadeh
704-384-8920
nnechiporchik@novanthealth.org

Novant Health Cancer Specialists-Matthews
Matthews, North Carolina 28105
Contact:
Nasfat Shehadeh
704-384-8920
nnechiporchik@novanthealth.org

Lake Norman Hematology Oncology Specialists-Mooresville
Mooresville, North Carolina 28117
Contact:
Nasfat Shehadeh
704-384-8920
nnechiporchik@novanthealth.org

FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina 28374
Contact:
Charles S. Kuzma
619-532-8712

Duke Raleigh Hospital
Raleigh, North Carolina 27609
Contact:
Jeffrey Crawford
888-275-3853

Sanford Bismarck Medical Center
Bismarck, North Dakota 58501
Contact:
Preston D. Steen
712-252-0088

Roger Maris Cancer Center
Fargo, North Dakota 58122
Contact:
Preston D. Steen
712-252-0088

Sanford Broadway Medical Center
Fargo, North Dakota 58122
Contact:
Preston D. Steen
712-252-0088

Sanford Clinic North-Fargo
Fargo, North Dakota 58122
Contact:
Preston D. Steen
712-252-0088

Trinity Cancer Care Center
Minot, North Dakota 58701
Contact:
Patanit Watanaboonyakhet
800-862-0005

Indu and Raj Soin Medical Center
Beavercreek, Ohio 45431
Contact:
Howard M. Gross
937-775-1350
som_dcop@wright.edu

Strecker Cancer Center-Belpre
Belpre, Ohio 45714
Contact:
Timothy D. Moore
800-523-3977
sheree@columbusccop.org

Mercy Medical Center
Canton, Ohio 44708
Contact:
Mitchell Haut
888-293-4673

Aultman Health Foundation
Canton, Ohio 44710
Contact:
Sunitha Vemulapalli
330-363-6891

Adena Regional Medical Center
Chillicothe, Ohio 45601
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

University of Cincinnati/Barrett Cancer Center
Cincinnati, Ohio 45219
Contact:
John C. Morris
513-558-4553
uchealthnews@uc.edu

MetroHealth Medical Center
Cleveland, Ohio 44109
Contact:
Bruce J. Averbook
216-778-8526
kbauchens@metrohealth.org

Cleveland Clinic Cancer Center/Fairview Hospital
Cleveland, Ohio 44111
Contact:
Aaron T. Gerds
866-223-8100

Cleveland Clinic Foundation
Cleveland, Ohio 44195
Contact:
Aaron T. Gerds
866-223-8100

Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
Contact:
Erin M. Bertino
800-293-5066
Jamesline@osumc.edu

Columbus Oncology and Hematology Associates Inc
Columbus, Ohio 43214
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Riverside Methodist Hospital
Columbus, Ohio 43214
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Grant Medical Center
Columbus, Ohio 43215
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

The Mark H Zangmeister Center
Columbus, Ohio 43219
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Mount Carmel Health Center West
Columbus, Ohio 43222
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Doctors Hospital
Columbus, Ohio 43228
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Good Samaritan Hospital - Dayton
Dayton, Ohio 45406
Contact:
Howard M. Gross
937-775-1350
som_dcop@wright.edu

Dayton Physicians LLC-Samaritan North
Dayton, Ohio 45415
Contact:
Howard M. Gross
937-775-1350
som_dcop@wright.edu

Samaritan North Health Center
Dayton, Ohio 45415
Contact:
Howard M. Gross
937-775-1350
som_dcop@wright.edu

Delaware Health Center-Grady Cancer Center
Delaware, Ohio 43015
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Cleveland Clinic Cancer Center Independence
Independence, Ohio 44131
Contact:
Aaron T. Gerds
866-223-8100

Kettering Medical Center
Kettering, Ohio 45429
Contact:
Howard M. Gross
937-775-1350
som_dcop@wright.edu

Cleveland Clinic Cancer Center Mansfield
Mansfield, Ohio 44906
Contact:
Aaron T. Gerds
866-223-8100

Marietta Memorial Hospital
Marietta, Ohio 45750
Contact:
Timothy D. Moore
800-523-3977
sheree@columbusccop.org

Hillcrest Hospital Cancer Center
Mayfield Heights, Ohio 44124
Contact:
Aaron T. Gerds
866-223-8100

Lake University Ireland Cancer Center
Mentor, Ohio 44060
Contact:
Afshin Dowlati
800-641-2422

Knox Community Hospital
Mount Vernon, Ohio 43050
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Licking Memorial Hospital
Newark, Ohio 43055
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Southern Ohio Medical Center
Portsmouth, Ohio 45662
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

North Coast Cancer Care
Sandusky, Ohio 44870
Contact:
Aaron T. Gerds
866-223-8100

Cleveland Clinic Cancer Center Strongsville
Strongsville, Ohio 44136
Contact:
Aaron T. Gerds
866-223-8100

Flower Hospital
Sylvania, Ohio 43560
Contact:
Abhijit B. Saste
419-824-1842

The Toledo Hospital/Toledo Children's Hospital
Toledo, Ohio 43606
Contact:
Abhijit B. Saste
419-824-1842

University of Toledo
Toledo, Ohio 43614
Contact:
Roland T. Skeel
419-383-6583

University Pointe
West Chester, Ohio 45069
Contact:
John C. Morris
513-558-4553
uchealthnews@uc.edu

Saint Ann's Hospital
Westerville, Ohio 43081
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

Cleveland Clinic Wooster Family Health and Surgery Center
Wooster, Ohio 44691
Contact:
Aaron T. Gerds
866-223-8100

Genesis Healthcare System Cancer Care Center
Zanesville, Ohio 43701
Contact:
Timothy D. Moore
614-488-2745
sheree@columbusccop.org

University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
Contact:
Mohammad A. Razaq
405-271-8777
ou-clinical-trials@ouhsc.edu

Oklahoma Cancer Specialists and Research Institute-Tulsa
Tulsa, Oklahoma 74146
Contact:
Mohammad A. Razaq
405-271-8777
ou-clinical-trials@ouhsc.edu

Saint Charles Health System
Bend, Oregon 97701
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Clackamas Radiation Oncology Center
Clackamas, Oregon 97015
Contact:
Gary E. Goodman
503-215-2614
CanRsrchStudies@providence.org

Providence Oncology and Hematology Care Southeast
Clackamas, Oregon 97015
Contact:
Gary E. Goodman
503-215-2614
CanRsrchStudies@providence.org

Legacy Mount Hood Medical Center
Gresham, Oregon 97030
Contact:
Jacqueline Vuky
503-413-1742

Providence Newberg Medical Center
Newberg, Oregon 97132
Contact:
Gary E. Goodman
503-215-2614
CanRsrchStudies@providence.org

Legacy Good Samaritan Hospital and Medical Center
Portland, Oregon 97210
Contact:
Jacqueline Vuky
503-413-1742

Providence Portland Medical Center
Portland, Oregon 97213
Contact:
Gary E. Goodman
503-215-2614
CanRsrchStudies@providence.org

Providence Saint Vincent Medical Center
Portland, Oregon 97225
Contact:
Gary E. Goodman
503-215-2614
CanRsrchStudies@providence.org

Kaiser Permanente Northwest
Portland, Oregon 97227
Contact:
Abdul H. Mansoor
503-335-2400

Oregon Health and Science University
Portland, Oregon 97239
Contact:
Khaled A. Tolba
503-494-1080
trials@ohsu.edu

Salem Hospital
Salem, Oregon 97301
Contact:
Natasha M. Tiffany
503-561-2618

Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania 18103
Contact:
Philip J. Stella
208-367-7954

Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania 18017
Contact:
Philip J. Stella
208-367-7954

Christiana Care Health System-Concord Health Center
Chadds Ford, Pennsylvania 19317
Contact:
Gregory A. Masters
302-733-6227

Geisinger Medical Center
Danville, Pennsylvania 17822
Contact:
Rajiv Panikkar
570-271-5251

Ephrata Cancer Center
Ephrata, Pennsylvania 17522
Contact:
Amir Tabatabai
877-441-7957

Adams Cancer Center
Gettysburg, Pennsylvania 17325
Contact:
Amir Tabatabai
877-441-7957

Cherry Tree Cancer Center
Hanover, Pennsylvania 17331
Contact:
Amir Tabatabai
877-441-7957

UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania 17109
Contact:
Rodney M. Jamil
717-724-6765
klitchfield@PINNACLEHEALTH.org

Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania 18201
Contact:
Rajiv Panikkar
570-271-5251

Sechler Family Cancer Center
Lebanon, Pennsylvania 17042
Contact:
Amir Tabatabai
877-441-7957

University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania 19104
Contact:
Charu Aggarwal
800-474-9892

Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111
Contact:
Hossein Borghaei
215-728-4790

Temple University Hospital
Philadelphia, Pennsylvania 19140
Contact:
Hossein Borghaei
215-728-4790

University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
Contact:
Liza C. Villaruz
412-647-8073

Geisinger Medical Oncology-Pottsville
Pottsville, Pennsylvania 17901
Contact:
Rajiv Panikkar
570-271-5251

Penn State Health Saint Joseph Medical Center
Reading, Pennsylvania 19605
Contact:
Chandra P. Belani
610-378-2336
danielward2@catholichealth.net

Guthrie Medical Group PC-Robert Packer Hospital
Sayre, Pennsylvania 18840
Contact:
Philip A. Lowry
800-836-0388

Community Medical Center
Scranton, Pennsylvania 18510
Contact:
Rajiv Panikkar
888-823-5923
ctsucontact@westat.com

Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania 18711
Contact:
Rajiv Panikkar
570-271-5251

UPMC Susquehanna
Williamsport, Pennsylvania 17701
Contact:
Warren L. Robinson
412-647-8073

WellSpan Health-York Cancer Center
York, Pennsylvania 17403
Contact:
Amir Tabatabai
877-441-7957

WellSpan Health-York Hospital
York, Pennsylvania 17403
Contact:
Amir Tabatabai
877-441-7957

Greenville Health System Cancer Institute-Easley
Easley, South Carolina 29640
Contact:
Jeffrey K. Giguere
864-679-3966

Gibbs Cancer Center-Gaffney
Gaffney, South Carolina 29341
Contact:
James D. Bearden
800-486-5941

Saint Francis Hospital
Greenville, South Carolina 29601
Contact:
Robert D. Siegel
864-255-1713

Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina 29605
Contact:
Jeffrey K. Giguere
864-679-3966

Greenville Health System Cancer Institute-Faris
Greenville, South Carolina 29605
Contact:
Jeffrey K. Giguere
864-679-3966

Saint Francis Cancer Center
Greenville, South Carolina 29607
Contact:
Robert D. Siegel
864-255-1713

Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina 29615
Contact:
Jeffrey K. Giguere
864-679-3966

Gibbs Cancer Center-Pelham
Greer, South Carolina 29651
Contact:
James D. Bearden
800-486-5941

Greenville Health System Cancer Institute-Seneca
Seneca, South Carolina 29672
Contact:
Jeffrey K. Giguere
864-679-3966

Spartanburg Medical Center
Spartanburg, South Carolina 29303
Contact:
James D. Bearden
800-486-5941

Greenville Health System Cancer Institute-Spartanburg
Spartanburg, South Carolina 29307
Contact:
Jeffrey K. Giguere
864-679-3966

Lexington Medical Center
West Columbia, South Carolina 29169
Contact:
Steven A. Madden
803-936-8050

Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota 57104
Contact:
Preston D. Steen
712-252-0088

Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota 57117-5134
Contact:
Preston D. Steen
712-252-0088

Cookeville Regional Medical Center
Cookeville, Tennessee 38501
Contact:
Thomas J. Summers
614-488-2745
sheree@columbusccop.org

Vanderbilt-Ingram Cancer Center Cool Springs
Franklin, Tennessee 37067
Contact:
Sally J. York
800-811-8480

Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee 38120
Contact:
Raymond U. Osarogiagbon
870-936-7000

Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee 37204
Contact:
Sally J. York
800-811-8480

Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
Contact:
Sally J. York
800-811-8480

The Don and Sybil Harrington Cancer Center
Amarillo, Texas 79106
Contact:
Anita Ravipati
806-212-1985
gcravey@harringtoncc.org

Parkland Memorial Hospital
Dallas, Texas 75235
Contact:
Saad A. Khan
214-590-5582

UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas 75390
Contact:
Saad A. Khan
214-590-5582

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas 77030
Contact:
Jun Zhang
713-798-1354
burton@bcm.edu

Ben Taub General Hospital
Houston, Texas 77030
Contact:
Jun Zhang
713-798-1354
burton@bcm.edu

M D Anderson Cancer Center
Houston, Texas 77030
Contact:
Vassiliki A. Papadimitrakopoulou
713-792-3245

Covenant Medical Center-Lakeside
Lubbock, Texas 79410
Contact:
Isaac Tafur
806-725-8000
jaccresearch@covhs.org

University Medical Center
Lubbock, Texas 79415
Contact:
Lukman A. Tijani
protocols@swog.org

Texas Tech University Health Sciences Center-Lubbock
Lubbock, Texas 79430
Contact:
Lukman A. Tijani
806-775-8590

University of Texas Health Science Center at San Antonio
San Antonio, Texas 78229
Contact:
Anand B. Karnad
877-469-5300

Sandra L Maxwell Cancer Center
Cedar City, Utah 84720
Contact:
Derrick S. Haslem
801-408-1347

Intermountain Medical Center
Murray, Utah 84107
Contact:
Derrick S. Haslem
801-408-1347

Dixie Medical Center Regional Cancer Center
Saint George, Utah 84770
Contact:
Derrick S. Haslem
801-408-1347

Central Vermont Medical Center/National Life Cancer Treatment
Berlin, Vermont 05602
Contact:
Hibba Tul Rehman
802-225-5400

University of Vermont Medical Center
Burlington, Vermont 05401
Contact:
Hibba Tul Rehman
802-656-4101

University of Vermont College of Medicine
Burlington, Vermont 05405
Contact:
Hibba Tul Rehman
802-656-8990

University of Virginia Cancer Center
Charlottesville, Virginia 22908
Contact:
Ryan D. Gentzler
434-243-6322
JME3D@hscmail.mcc.virginia.edu

Sovah Health Martinsville
Martinsville, Virginia 24115
Contact:
Sreedhar Katragadda
276-666-7827

Bon Secours Memorial Regional Medical Center
Mechanicsville, Virginia 23116
Contact:
William J. Irvin
877-668-0683
cancerclinicaltrials@med.unc.edu

Bon Secours Saint Francis Medical Center
Midlothian, Virginia 23114
Contact:
William J. Irvin
877-668-0683
cancerclinicaltrials@med.unc.edu

Bon Secours Saint Mary's Hospital
Richmond, Virginia 23226
Contact:
William J. Irvin
877-668-0683
cancerclinicaltrials@med.unc.edu

Virginia Cancer Institute
Richmond, Virginia 23230
Contact:
Sarah W. Gordon
888-823-5923
ctsucontact@westat.com

Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia 23298
Contact:
Sarah W. Gordon
888-823-5923
ctsucontact@westat.com

MultiCare Auburn Medical Center
Auburn, Washington 98001
Contact:
John A. Keech
907-458-5380

Overlake Hospital Medical Center
Bellevue, Washington 98004
Contact:
John A. Keech
907-458-5380

PeaceHealth Saint Joseph Medical Center
Bellingham, Washington 98225
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Swedish Medical Center-Edmonds
Edmonds, Washington 98026
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Tacoma/Valley Radiation Oncology Centers-Gig Harbor
Gig Harbor, Washington 98332
Contact:
John A. Keech
907-458-5380

MultiCare Gig Harbor Medical Park
Gig Harbor, Washington 98335
Contact:
John A. Keech
907-458-5380

Swedish Cancer Institute-Issaquah
Issaquah, Washington 98029
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Kadlec Clinic Hematology and Oncology
Kennewick, Washington 99336
Contact:
Christina S. Baik
800-422-6237

Northwest Cancer Clinic
Kennewick, Washington 99336
Contact:
John A. Keech
509-987-1800
info@tacomaradiation.com

Seattle Cancer Care Alliance at EvergreenHealth
Kirkland, Washington 98034
Contact:
Christina S. Baik
800-422-6237

PeaceHealth Saint John Medical Center
Longview, Washington 98632
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Skagit Valley Hospital Regional Cancer Care Center
Mount Vernon, Washington 98273
Contact:
Christina S. Baik
800-422-6237

Skagit Valley Hospital
Mount Vernon, Washington 98274
Contact:
Christina S. Baik
800-422-6237

Jefferson Healthcare
Port Townsend, Washington 98368
Contact:
John A. Keech
907-458-5380

MultiCare Good Samaritan Hospital
Puyallup, Washington 98372
Contact:
John A. Keech
907-458-5380

Tacoma/Valley Radiation Oncology Centers-Puyallup
Puyallup, Washington 98372
Contact:
John A. Keech
907-458-5380

Swedish Medical Center-Ballard Campus
Seattle, Washington 98107
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Fred Hutchinson Cancer Research Center
Seattle, Washington 98109
Contact:
Christina S. Baik
800-422-6237

Seattle Cancer Care Alliance
Seattle, Washington 98109
Contact:
Christina S. Baik
800-422-6237

Swedish Medical Center-First Hill
Seattle, Washington 98122-4307
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Seattle Cancer Care Alliance at Northwest Hospital
Seattle, Washington 98133
Contact:
Christina S. Baik
800-422-6237

University of Washington Medical Center
Seattle, Washington 98195
Contact:
Christina S. Baik
800-422-6237

MultiCare Tacoma General Hospital
Tacoma, Washington 98405
Contact:
John A. Keech
907-458-5380

PeaceHealth Southwest Medical Center
Vancouver, Washington 98664
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Legacy Salmon Creek Hospital
Vancouver, Washington 98686
Contact:
Jacqueline Vuky
503-413-1742

Providence Saint Mary Regional Cancer Center
Walla Walla, Washington 99362
Contact:
Gary E. Goodman
907-212-6871
AKPAMC.OncologyResearchSupport@providence.org

Wenatchee Valley Hospital and Clinics
Wenatchee, Washington 98801
Contact:
Christina S. Baik
800-422-6237

West Virginia University Charleston
Charleston, West Virginia 25304
Contact:
Steven J. Jubelirer
304-388-9944

Saint Mary's Medical Center
Huntington, West Virginia 25702
Contact:
Arvinder S. Bir
888-823-5923
ctsucontact@westat.com

West Virginia University Healthcare
Morgantown, West Virginia 26506
Contact:
Patrick C. Ma
866-223-8100

Camden-Clark Memorial Hospital
Parkersburg, West Virginia 26101
Contact:
Patrick C. Ma
866-223-8100

Aurora Cancer Care-Southern Lakes VLCC
Burlington, Wisconsin 53105
Contact:
Rubina Qamar
414-649-5717

Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin 54729
Contact:
Adedayo A. Onitilo
800-347-0673

Marshfield Clinic Cancer Center - Eau Claire
Eau Claire, Wisconsin 54701
Contact:
Adedayo A. Onitilo
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Aurora Health Center-Fond du Lac
Fond Du Lac, Wisconsin 54937
Contact:
Rubina Qamar
414-649-5717

Aurora Health Care Germantown Health Center
Germantown, Wisconsin 53022
Contact:
Rubina Qamar
414-649-5717

Aurora Cancer Care-Grafton
Grafton, Wisconsin 53024
Contact:
Rubina Qamar
414-649-5717

Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin 54301-3526
Contact:
Matthew L. Ryan
920-433-8889

Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin 54301
Contact:
Matthew L. Ryan
920-433-8889
Christy.Gilchrist@hshs.org

Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin 54303
Contact:
Matthew L. Ryan
920-433-8889
Christy.Gilchrist@hshs.org

Aurora BayCare Medical Center
Green Bay, Wisconsin 54311
Contact:
Rubina Qamar
414-649-5717

Mercy Health System
Janesville, Wisconsin 53547
Contact:
Emily G. Robinson
800-928-1103

UW Cancer Center Johnson Creek
Johnson Creek, Wisconsin 53038
Contact:
Anne M. Traynor
608-256-1901

Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin 53142
Contact:
Rubina Qamar
414-649-5717

Gundersen Lutheran Medical Center
La Crosse, Wisconsin 54601
Contact:
Kurt Oettel
920-433-8889
Christy.Gilchrist@hshs.org

Marshfield Clinic - Ladysmith Center
Ladysmith, Wisconsin 54848
Contact:
Adedayo A. Onitilo
800-347-0673

University of Wisconsin Hospital and Clinics
Madison, Wisconsin 53792
Contact:
Anne M. Traynor
608-256-1901

Holy Family Memorial Hospital
Manitowoc, Wisconsin 54221
Contact:
Matthew L. Ryan
920-433-8889
Christy.Gilchrist@hshs.org

Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin 54143
Contact:
Rubina Qamar
414-649-5717

Saint Vincent Hospital Cancer Center at Marinette
Marinette, Wisconsin 54143
Contact:
Matthew L. Ryan
920-433-8889
Christy.Gilchrist@hshs.org

Vince Lombardi Cancer Clinic-Marinette
Marinette, Wisconsin 54143
Contact:
Rubina Qamar
414-649-5717

Marshfield Clinic
Marshfield, Wisconsin 54449
Contact:
Adedayo A. Onitilo
800-347-0673

Marshfield Medical Center
Marshfield, Wisconsin 54449
Contact:
Adedayo A. Onitilo
800-347-0673

Aurora Cancer Care-Milwaukee
Milwaukee, Wisconsin 53209
Contact:
Rubina Qamar
414-649-5717

Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin 53215
Contact:
Rubina Qamar
414-649-5717

Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin 53226
Contact:
Smitha P. Menon
952-993-1517
mmcorc@healthpartners.com

Aurora Sinai Medical Center
Milwaukee, Wisconsin 53233
Contact:
Rubina Qamar
414-649-5717

Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin 54548
Contact:
Adedayo A. Onitilo
800-347-0673

Green Bay Oncology - Oconto Falls
Oconto Falls, Wisconsin 54154
Contact:
Matthew L. Ryan
920-433-8889
Christy.Gilchrist@hshs.org

Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin 54904
Contact:
Rubina Qamar
414-649-5717

Aurora Cancer Care-Racine
Racine, Wisconsin 53406
Contact:
Rubina Qamar
414-649-5717

Lakeview Medical Center-Marshfield Clinic
Rice Lake, Wisconsin 54868
Contact:
Adedayo A. Onitilo
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Marshfield Clinic-Rice Lake Center
Rice Lake, Wisconsin 54868
Contact:
Adedayo A. Onitilo
800-347-0673

Vince Lombardi Cancer Clinic-Sheboygan
Sheboygan, Wisconsin 53081
Contact:
Rubina Qamar
414-649-5717

Marshfield Clinic Stevens Point Center
Stevens Point, Wisconsin 54482
Contact:
Adedayo A. Onitilo
800-347-0673

Saint Vincent Hospital Cancer Center at Sturgeon Bay
Sturgeon Bay, Wisconsin 54235-1495
Contact:
Matthew L. Ryan
920-433-8889
Christy.Gilchrist@hshs.org

Aurora Medical Center in Summit
Summit, Wisconsin 53066
Contact:
Rubina Qamar
414-649-5717

Marshfield Clinic-Wausau Center
Wausau, Wisconsin 54401
Contact:
Adedayo A. Onitilo
800-347-0673

Aurora Cancer Care-Milwaukee West
Wauwatosa, Wisconsin 53226
Contact:
Rubina Qamar
414-649-5717

Aurora West Allis Medical Center
West Allis, Wisconsin 53227
Contact:
Rubina Qamar
414-649-5717

Diagnostic and Treatment Center
Weston, Wisconsin 54476
Contact:
Adedayo A. Onitilo
800-347-0673

Marshfield Clinic - Weston Center
Weston, Wisconsin 54476
Contact:
Adedayo A. Onitilo
800-347-0673

Aspirus UW Cancer Center
Wisconsin Rapids, Wisconsin 54494
Contact:
Harish G. Ahuja
877-405-6866

Marshfield Clinic - Wisconsin Rapids Center
Wisconsin Rapids, Wisconsin 54494
Contact:
Adedayo A. Onitilo
800-347-0673

Billings Clinic-Cody
Cody, Wyoming 82414
Contact:
Benjamin T. Marchello
406-969-6060
mccinfo@mtcancer.org

More Details

NCT ID
NCT02154490
Status
Recruiting
Sponsor
Southwest Oncology Group

Detailed Description

PRIMARY OBJECTIVES:

Screening component:

I. To establish a National Clinical Trials Network (NCTN) mechanism for genomically screening large but homogeneous cancer populations and subsequently assigning and accruing simultaneously to a multi-sub-study ?Master Protocol.? II. To evaluate the screen success rate defined as the percentage of screened patients that register for a therapeutic sub-study.

Sub-study-specific Objectives:

Design #1: Phase II/III Design:

III. To evaluate if there is sufficient evidence to continue to the Phase III component of the sub-study by comparing investigator-assessed progression-free survival (IA-PFS) between investigational therapy versus standard therapy (SoC) in patients with advanced stage refractory squamous cell carcinoma (SCCA) of the lung. (Phase II) IV. To determine if there is both a statistically and clinically-meaningful difference in IA-PFS among advanced stage refractory SCCA of the lung randomized to receive investigational therapy versus SoC. (Phase III) V. To compare overall survival (OS) in patients with advanced stage refractory SCCA of the lung randomized to investigational therapy versus SoC. (Phase III)

Design #2: Phase II followed by Phase III (Sequential Phase II to Phase III):

VI. To evaluate the objective response rate (confirmed and unconfirmed, complete and partial). (Phase II) VII. To determine if there is both a statistically and clinically-meaningful difference in IA-PFS among advanced stage refractory SCCA of the lung randomized to receive investigational therapy versus SoC. (Phase III) VIII. To compare overall survival (OS) in patients with advanced stage refractory SCCA of the lung randomized to investigational therapy versus SoC. (Phase III)

SECONDARY OBJECTIVES:

Sub-study-specific Objectives:

Design #1: Phase II/III Design:

I. To compare response rates (confirmed and unconfirmed, complete and partial responses) among patients randomized to receive investigational therapy versus SoC. (Phase II) II. To evaluate the frequency and severity of toxicities associated with investigational therapy versus SoC. (Phase II) III. To evaluate the duration of response (DoR) among patients who achieve a complete response (CR) or a partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) (1.1). (Phase II) III. To compare the response rates (confirmed and unconfirmed, complete and partial) among patients randomized to receive investigational therapy versus SoC. (Phase III) IV. To evaluate the frequency and severity of toxicities associated with investigational therapy versus SoC. (Phase III)

Design #2: Phase II followed by Phase III (Sequential Phase II to Phase III):

V. To evaluate PFS and OS with investigational therapy. (Phase II) VI. To evaluate the DoR among patients who achieve a CR or PR (confirmed and unconfirmed) by RECIST 1.1. (Phase II) VII. To evaluate the frequency and severity of toxicities associated with investigational therapy. (Phase II) VIII. To compare the response rates (confirmed and unconfirmed, complete and partial) among patients randomized to receive investigational therapy versus SoC. (Phase III) IX. To evaluate the frequency and severity of toxicities associated with investigational therapy versus SoC. (Phase III)

TERTIARY OBJECTIVES:

I. To evaluate the treatment arm randomization acceptance rate (TARAR) within each treatment arm of each sub-study defined as the percentage of patients randomized to a treatment arm that receive any protocol treatment. (Design #1: Phase II/III Design) II. To identify additional predictive tumor/blood biomarkers that may modify response or define resistance to the targeted therapy (TT)/targeted therapy combination (TTC) beyond the chosen biomarker for biomarker-driven sub-studies.

III. To evaluate potentially predictive biomarkers for non-match therapy (NMT) in the non-match studies.

IV. To identify potential resistance biomarkers at disease progression. V. To establish a tissue/ blood repository from patients with refractory SCCA of the lung.

OUTLINE: Patients are assigned to a biomarker-driven targeted therapy phase II study. If the objectives response rate observed is judged sufficient, patients proceed to a randomized phase III trial and are randomized to biomarker-driven targeted therapy or standard of care.

S1400A: (CLOSED TO ACCRUAL 12/18/2015) Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study are assigned to Arm I. Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period (Arm III).

ARM I: (CLOSED TO ACCRUAL 12/18/2015) Patients receive anti-B7H1 monoclonal antibody MEDI4736 intravenously (IV) over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.

ARM II (CLOSED TO ACCRUAL 4/2015): Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #2 4/22/15)

ARM III: For patients assigned to Arm 1, MEDI4736: Upon evidence of progression following discontinuation of 12 months of treatment, patients may restart treatment with Arm 3, MEDI4736 for up to 12 months with the same treatment guidelines followed during the initial 12-month treatment period. Patients will only be able to restart treatment once; thus a maximum of two 12-month periods will be allowed. Patients receive anti-B7H1 monoclonal antibody MEDI4736 intravenously (IV) over 60 minutes on day 1. Treatment repeats every 14 days for 12 months in the absence of disease progression or unacceptable toxicity.

S1400B (CLOSED TO ACCRUAL 12/12/2016): Patients with tumors positive for phosphoinositide 3-kinase (PI3KCA) are assigned to Arm I. Patients currently on Arm 2, docetaxel will be given the option to re-register to Arm 3, GCD-0032 after disease progression on current treatment (Arm III).

ARM I: Patients receive taselisib orally (PO) daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II (CLOSED TO ACCRUAL 12/18/2015): Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)

ARM III: Re-Registration Treatment with GDC-0032 (Taselisib) Upon progression patients in Arm 2 may be eligible for Re-Registration to receive GDC-0032. Patients receive taselisib orally (PO) daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

S1400C (CLOSED TO ACCRUAL 09/01/2016): Patients with tumors positive for cyclin dependent kinase 4 (CDK4), cyclin D1 (CCND1), cyclin D2 (CCND2), and cyclin D3 (CCND3) are assigned to Arm I. Patients currently on Arm 2, docetaxel will be given the option to re-register to Arm 3, palbociclib, after disease progression on current treatment (Arm III).

ARM I: Patients receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

ARM II (CLOSED TO ACCRUAL 12/18/2015): Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)

ARM III: Re-Registration Treatment with Palbociclib. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive palbociclib. Patients receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

S1400D (CLOSED TO ACCRUAL 10/31/2016): Patients with tumors positive for fibroblast growth factor receptor (FGFR) 1, FGFR2, and FGFR3 are assigned to Arm I. Patients currently on Arm 2, docetaxel will be given the option to re-register to Arm 3, AZD4547, after disease progression on current treatment (Arm III).

ARM I: Patients receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II (CLOSED TO ACCRUAL 12/18/2015): Patients receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (closed to accrual with Revision #3 12/18/2015)

ARM III: Re-Registration Treatment with AZD4547. Upon progression patients in Arm 2 may be eligible for Re-Registration to receive AZD4547. Patients receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

S1400E (CLOSED TO ACCRUAL 11/25/2014): Patients with tumors positive for met proto-oncogene (MET) are randomized to 1 of 2 treatment arms. (permanently closed to accrual on 11/25/14)

ARM I: Patients receive rilotumumab IV on day 1 and erlotinib hydrochloride PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive erlotinib hydrochloride PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

S1400F: Patients with disease progression during or after prior anti-PD-1 or anti-PD-L1 antibody monotherapy as their most recent line of treatment receive durvalumab (IV over 60 minutes) and tremelimumab (IV over 60 minutes) on day 1 for courses 1-4 and durvalumab IV alone on day 1 of course 5 and subsequent courses until disease progression or unacceptable toxicity. Courses repeat every 28 days.

S1400G: Patients with tumors positive for homologous recombination repair deficiency receive talazoparib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

S1400I: Patients with tumors that do not match one of the currently active drug-biomarker combinations or did not meet the eligibility requirements for that bio-marker driven sub-study are randomized to 1 of 2 treatment arms.

ARM I: Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, all patients are followed up periodically for up to 3 years from date of screening registration.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.